Table 1.
Patients and tumor characteristics
| EVA study (n = 81) | GIM-13 AMBRA study (n = 91) | |
|---|---|---|
| Median age (range), years | 63 (35–82) | 57.8 (35.0–82.3) |
| ECOG PS | 79/81 | n.a. |
| 0–1 | 95 | |
| ≥2 | 5 | |
| Hormone receptor status | ||
| ER+ve | 96 | 49 |
| PgR+ve | 87 | 51 |
| Metastatic sites | ||
| Bone | 70 | 57.1 |
| Soft tissue | 42 | n.a. |
| Viscera | 41 | 30.8 |
| Number of metastatic sites | ||
| 1 | 10 | |
| 2 | 32 | |
| ≥3 | 57 | |
| Adjuvant endocrine therapy | 57.51 | 96.7 |
| Tamoxifen ± LHRH | 26.73 | 48.8 |
| Als | 30.78 | 36.3 |
Values are presented as percentages, unless otherwise indicated. n.a., not available.